New Survey: Most US Adults Support Vaccines, but Many Remain Unclear About Respiratory Vaccine Recommendations

NFID's survey found that only 48% of US adults tried to receive at least one flu, COVID-19, RSV, or pneumococcal vaccine in the past year, despite 77% viewing vaccines as among the best protections against serious infectious disease. Flu-vaccine attempts reached 44%, while COVID-19 vaccine attempts were only 23%; 22% of adults who sought a respiratory vaccine reported access problems. NFID launched the National Respiratory Communications Initiative to improve clarity around vaccine recommendations and reduce access and information barriers before respiratory season.

Analysis

This is not a demand inflection signal for vaccine manufacturers; it is a channel-execution signal. Incremental uptake will accrue disproportionately to products with broad adult eligibility and simple pharmacy workflow—GSK's AREXVY, PFE's ABRYSVO, MRK's CAPVAXIVE, and SNY's flu franchise—rather than COVID products, where policy ambiguity and weak consumer intent remain the binding constraints. The reported friction at point of care creates a second-order opportunity for retail pharmacy operators and PBM-linked networks, but WMT's vaccine contribution remains immaterial to consolidated earnings.

For the next 1-3 months, the relevant catalyst is whether pharmacy inventory, reimbursement adjudication, and clinician prompts convert educational outreach into administered doses before peak respiratory season. A modest lift in flu vaccination is unlikely to alter large-cap estimates, whereas RSV and pneumococcal doses carry higher revenue per encounter and can matter at the margin for GSK, PFE, and MRK given their more concentrated adult-vaccine growth narratives. Investors should demand weekly/state-level administration data or company commentary before extrapolating survey intent into revenue.

The contrarian read is that access failures—not sentiment—make vaccine sales more operationally elastic than consensus assumes. That supports a relative preference for companies able to activate pharmacists and health-system accounts, but it also raises the risk of inventory write-downs if campaigns arrive after seasonal purchasing decisions. The thesis is falsified by unchanged CDC/IQVIA administration trends through late October, reduced 2026 vaccine guidance, or new ACIP eligibility restrictions; in that case, vaccine multiples should compress as growth is again deferred rather than lost temporarily.

Longer term, repeated confusion around adult schedules favors combination products and portfolio breadth, potentially advantaging PFE and GSK over single-franchise exposure. However, any broadening of COVID uptake should not be assumed: it would require a materially more severe season, clearer federal guidance, or employer/health-plan incentives, none of which is established by a sponsor-supported communications initiative.

Key Decisions for Investors

• No outright trade on the release alone; set a late-October watch trigger on verified RSV and pneumococcal administration data. Upgrade GSK/MRK only if volumes show sustained year-on-year acceleration, not merely improved awareness.
• Prefer a 3-6 month relative-value long GSK / short PFE only after RSV prescription data confirm GSK share retention and PFE does not offset with stronger ABRYSVO uptake. Target 10-15% relative return; exit on a meaningful PFE share gain or GSK vaccine-guidance reduction.
• Monitor MRK for pneumococcal channel execution: CAPVAXIVE upside requires evidence that pharmacy and primary-care friction is declining. A positive administration-data surprise can support a tactical long into earnings; absent that evidence, avoid assigning incremental sales to estimates.
• Do not use WMT as a vaccine-demand expression. Pharmacy traffic may benefit marginally, but earnings sensitivity is too diluted; use CVS or WBA only if separate reimbursement and vaccine-traffic data demonstrate a material seasonal contribution.